Search for a trial | Research with human participants

1 results

Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity

Approved WMORecruiting

This study has been transitioned to CTIS with ID 2023-506929-11-00 check the CTIS register for the current data. Primary To confirm superiority on body weight reduction of CagriSema 2.4 mg/2.4 mg versus placebo as adjuncts to reduced-calorie diet…